Biosimilars advancements: Moving on to the future

Many patents for the first biologicals derived from recombinant technology and, more recently, monoclonal antibodies (mAbs) are expiring. Naturally, biosimilars are becoming an increasingly important area of interest for the pharmaceutical industry worldwide, not only for emergent countries that nee...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuruta, Lilian Rumi, Lopes dos Santos, Mariana, Moro, Ana Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
SPECIAL SECTION: Articles presented at the Cell Culture Engineering XIV (CCE XIV) conference, Québec city, Canada, May 4–9, 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681164/
https://www.ncbi.nlm.nih.gov/pubmed/25708573
http://dx.doi.org/10.1002/btpr.2066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681164/
https://www.ncbi.nlm.nih.gov/pubmed/25708573
http://dx.doi.org/10.1002/btpr.2066

Ejemplares similares